SUCLA2 gene is frequently involved in the deletion of RB1 gene region, which occurs in 10 – 30 % of advanced prostate cancers. SUCLA2 deletion gives rise to a metabolic vulnerability. By screening chemical compounds, thymoquinone appeared to selectively kill SUCLA2-deficeint prostate cancer cells.
Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patients.
Hormone therapy is often chosen for the treatment of metastatic prostate cancer but nearly half of patients develop resistance to the treatment in as little as 2 years. A mutation in RB1, a tumor suppressor gene that keeps cell growth under control, has been pegged as a particularly strong driver of treatment resistance and predicts poor outcome in patients.
“Mutations in tumor suppressor genes are enough to induce initiation and malignant progression of prostate cancer, but so far we haven’t been able to directly target these mutations with drugs to treat prostate cancer,” says the lead author Susumu Kohno. “We wanted to find a genetic aberration associated with that of a tumor suppressor gene which we could target therapeutically.”
In the genome, SUCLA2 neighbors RB1. An analysis of prostate cancer cells showed that cells with a RB1 deletion were also missing SUCLA2, pairing up the SUCLA2 deletion with the RB1 deletion present in advanced stage prostate cancer. Kohno and colleagues analyzed prostate cancer tissue and found that 11% of cases were missing both SUCLA2 and RB1.
The researchers screened compounds to identify drugs that would selectively kill cells with a SUCLA2 deletion. Out of around 2,000 compounds, TQ emerged as a hit compound. TQ already has known anti-cancer effects and was shown to be safe in a phase I clinical trial. Kohno and colleagues applied the TQ treatment to a mouse model of SUCLA2-deficient prostate cancer and TQ selectively suppressed tumor growth.
“These findings show that TQ treatment could be an effective therapy for treating prostate cancer cells that harbor SUCLA2 deficiency” says the senior author Chiaki Takahashi.
In a search of genetic databases from patients with prostate cancer, the researchers found that the frequency of SUCLA2 loss was almost perfectly aligned with RB1 loss at every disease stage—meaning the SUCLA2 deletion could identify people with prostate cancer needing advanced therapy.
Finding this drug-targetable vulnerability opens a crack in the barrier of treatment resistance for prostate cancer. More work needs to be done to improve efficacy of TQ and identify patients that would benefit from this type of treatment, but the compound provides a promising route for new treatment options for advanced prostate cancer.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Advanced prostate cancer
- Telix Commences Phase III Clinical Trial of Prostate Canceron May 16, 2021 at 3:48 am
Body> MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) app ...
- Astellas’ Xtandi bags additional MHRA approval in prostate canceron May 12, 2021 at 2:04 am
Once-daily oral Xtandi approved for the treatment of adult men with metastatic hormone-sensitive prostate cancer ...
- Telix begins Phase III prostate cancer treatment trialon May 10, 2021 at 9:25 am
Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) ...
- Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Canceron May 10, 2021 at 1:27 am
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) announced today that the European Commission (EC) has approved an additional indication for the oral once-daily ...
- Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trialon May 9, 2021 at 8:20 pm
Telix Pharmaceuticals (ASX:TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in prostate cancer patients.
Go deeper with Google Headlines on:
Advanced prostate cancer
Go deeper with Bing News on:
- Discovery of primary prostate cancer biomarkers using cross cancer learningon May 17, 2021 at 2:43 pm
Prostate cancer (PCa), the second leading cause of cancer death in American men, is a relatively slow-growing malignancy with multiple early treatment options. Yet, a significant ...
- ‘Tiger King’ star Joe Exotic wants President Biden to pardon him so he can get ‘proper medical care’ for prostate canceron May 17, 2021 at 2:10 pm
Tiger King” star Joe Exotic (Joseph Maldonado-Passage) wants President Joe Biden to grant him clemency so he can receive “proper medical care” for prostate cancer.
- Did Joe Exotic Say He Had Prostate Cancer?on May 16, 2021 at 11:53 am
On May 14, 2021, reality star Joe Exotic revealed on social media that he believed he had prostate cancer and asked U.S. President Joe Biden and other political leaders to sign a pardon releasing him ...
- Joe Exotic gives health update after revealing prostate cancer scare, asking for Biden pardon: 'Wish me luck'on May 16, 2021 at 10:15 am
Tiger King star Joe Maldonado-Passage — best known as Joe Exotic — revealed he may have prostate cancer in a message to fans on social media Friday. The Netflix star and former zoo operator, who is ...
- 'Tiger King' star Joe Exotic reveals he has prostate cancer and wants Biden to pardon him so that he can get 'proper medical care'on May 16, 2021 at 3:46 am
Joe Exotic, who is serving a 22-year jail sentence, has asked President Joe Biden for a pardon so that he can get treated for prostate cancer at home.